#ALLsm
LightNews LightNews
markgeyermd.bsky.social
Dr. Jabbour from @mdanderson.bsky.social presents on long-term outcomes following obecabtagene autoleucel (obe-cel, Aucatzyl) stratified by depth of response by clonoSEQ NGS (sensitivity 10^-6). 84% of responders achieved clonoSEQ negativity. 1/x #ash24 #allsm
December 10, 2024 at 1:09 AM
markgeyermd.bsky.social
Dr. Short from @mdanderson.bsky.social presents an update on their ponatinib/blinatumomab (pon/blin) experience. Regimen updated to include 15 LPs (rather than 12) to protect against CNS relapse. Pts w/ persistent BCR::ABL were clonoSEQ neg, suggesting BCR::ABL wasn't MRD. 1/x #ash24 #allsm
December 9, 2024 at 11:28 PM
vjhemonc.bsky.social
In an interview from #ASH24, @nitinjainmd.bsky.social of @mdanderson.bsky.social discusses an analysis assessing the safety of discontinuing TKIs in patients with Ph+ ALL not undergoing alloSCT.

Click here to watch:
👉 https://buff.ly/4hqSeue 👈

#ALLsm #Leusm #Leukemia #HemOnc
February 3, 2025 at 5:00 PM
swog.org
Trial S1905 tests OBI-3424 treatment for patients w relapsed or refractory T-ALL or T-LBL. Phase 1 has completed; phase 2 is now testing for efficacy and toxicities. Also measuring the rate of MRD negativity in patients with CR or CRi. #HemOnc #ALLsm #lymphoma
@fredhutch.bsky.social
Trial S1905
July 29, 2025 at 7:39 PM
markgeyermd.bsky.social
Higher WBC at dx, CNS dz at dx, VPREB1 deletion associated w/ higher risk of relapse. Neither p190 vs p210 nor IKZF1+ phenotype predicted relapse. 3-year OS 88%. How to intensify therapy for HR BCR::ABL+ ALL and how/if to transition off TKI safely unclear. 2/2 #ash24 #allsm
December 9, 2024 at 11:29 PM
markgeyermd.bsky.social
Dr. Monika Brüggemann presents on a novel subtype of lenalidomide-associated B-ALL (IDH2 mutations from clonal hematopoiesis and acquired IKZF1 deletions). 58 pts, 56/58 BCR::ABL negative, median age 65. Curiously, distinct subtype had IDH2 mutations. 1/x #allsm #ASH24
December 9, 2024 at 12:56 AM
markgeyermd.bsky.social
Dr. Nicola Goekbuget from Goethe University, University Hospital, Frankfurt reports on results of GMALL 08/2013 (age 18-55); this included randomization for Ph-neg HR ALL pts w/ available donor and molecular CR (<0.01% by qPCR) after induction phase 2 (IP2). 1/x #ash24 #allsm
December 10, 2024 at 12:42 AM
vjhemonc.bsky.social
#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:

🎥 buff.ly/s2zXiCa

#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
October 29, 2025 at 5:42 PM
vjhemonc.bsky.social
At #CART25 last week, Pere Barba of @vhio.bsky.social shared updated results from the FELIX trial, evaluating obe-cel in patients with R/R ALL.

Watch the interview here:
👉 https://buff.ly/40SDhKF 👈

#ALLsm #Leusm #CTSM #TrialUpdate #ImmunoOnc #MedSky #BloodSky #HemeSky #HemeOnc
February 13, 2025 at 5:04 PM
markgeyermd.bsky.social
Dr. Nicolas Boissel discusses predictors of isolated CNS (iCNS) relapse across GRAALL-2005 to -2014 (adults w/ ND BCR::ABL neg ALL). Population = 1530 pts. Higher risk of isolated CNS relapse in GRAALL 2014. Lack of alloHCT and higher b/l WBC assoc w/ higher risk of iCNS relapse. 1/x #ASH24 #allsm
December 9, 2024 at 7:36 PM
markgeyermd.bsky.social
Dr. Martin Schrappe presents on outcomes in pediatric pts w/ T-ALL on AIEOP-BFM ALL 2009. Key question: can modeling help adjust risk stratification? Key changes: dex after pred pre-phase, addition of cyclophos for pred poor responders. 1/x #ASH24 #allsm
December 9, 2024 at 7:23 PM
markgeyermd.bsky.social
Dr. Ibrahim Aldoss from @cityofhope.bsky.social presents data on definitive CD19-targeted CAR T-cell therapy in pts ≥55 years w/ B-cell ALL in CR1. Lower disease burden pre-conditioning/LDC associated w/ ↓ toxicity and ↑ LFS. Pilot study schema as below. #ash24 #allsm 1/x
December 10, 2024 at 1:54 AM
markgeyermd.bsky.social
Jieping Lin from Southern Medical University, Guangzhou, China presents on the HDAC inhibitor (HDACi) tucidinostat + pediatric-inspired chemo in pts age 14-55 w/ ETP-ALL/LBL. Role of HDACi hypothesized based on recurrent mutations in histone-modifying genes. 1/x #allsm #ash24
December 9, 2024 at 11:54 PM
markgeyermd.bsky.social
Lack of CR at EOI or MRD negativity at EOC in HR pts was negative predictor of EFS. Several models then designed to integrate CNS status, EOI and EOC MRD. EOC MRD (strongest) and CNS-3 continue to be relevant prognostic factors. 2/x #ASH24 #allsm
December 9, 2024 at 7:23 PM
markgeyermd.bsky.social
Dr. Michela Ansuinelli from Sapienza University of Rome reports on immunomodulatory effect of DAS + BLIN vs PON + BLIN in ND BCR::ABL+ ALL. Previous reports: DAS + BLIN ↑ NK, T-NK and CD8+ T cells, and a ↓of (Tregs), more evident after repeated cycles of BLIN. 1/x #allsm #ash24
December 9, 2024 at 11:40 PM
markgeyermd.bsky.social
Assessed circulating immune cells in 110 PON/BLIN recipients (compared w/ 43 DAS/BLIN). ↑NK, T-NK and Treg immunomod w/ DAS/BLIN (vs PON/BLIN). ↑T-cells, NK, NK-T, ↓Tregs w/ DAS/BLIN. NK-T cells in DAS/BLIN pts showed ↑CD25/CD69 (activation) and ↓exhaustion markers (PD1+TIM3+). 2/2 #allsm #ash24
December 9, 2024 at 11:42 PM
markgeyermd.bsky.social
Dr. Jing Pan from Beijing Gobroad Hospital presents update on outcomes post-donor derived CD7 CAR T-cell therapy for pts w/ R/R T-ALL/LBL. Risks of relapse and death from infection significant in prior studies; authors aimed to clarify predictors of survival in 75 pts. 1/x #ash24 #allsm
December 10, 2024 at 1:22 AM
myelomateacher.bsky.social
First interview of the #EHA25 Day 2. Dr. Litzow of @MayoClinic #mmsm #allsm Remember stop by and share your research. Hearing about your research provides patients with hope. We are located across from Coral 4!
June 13, 2025 at 7:25 AM
markgeyermd.bsky.social
TCF3::PBX1 subgroup had ↑risk of iCNS relapse among those w/ B-ALL. ↑EOI had ↓ risk of iCNS relapse, likely due to ↑rates of alloHCT and ↑BM relapses in MRD+ pts. As we de-intensify frontline chemotx, including w/ immunotx, need to keep CNS ppx in mind given risks of CNS relapse. 2/2 #ASH24 #allsm
December 9, 2024 at 7:38 PM
vjhemonc.bsky.social
Hear about the status of #CARTCell therapy in acute and chronic leukemias (ALL, AML, CLL) in our interview from #CART25 with Ulrich Jäger:

👉 https://buff.ly/3QhuKfw 👈

#Leusm #Leukemia #ALLsm #AMLsm #CLLsm #ImmunoOnc #HemOnc
February 20, 2025 at 11:00 AM
vjhemonc.bsky.social
MYC is required for tumor maintenance & presents a potential target for the treatment of acute leukemias.🩸

Learn about the development of strategies targeting MYC from Michael Andreeff:

👉 buff.ly/IY0vaTp 👈

#Leusm #AMLsm #ALLsm #ISAL2025 #HemOnc #Hematology #MedSky #BloodSky #HemeSky
April 7, 2025 at 9:01 AM
markgeyermd.bsky.social
14 pts treated so far. Good expansion in PB/CSF. G1 CRS 64%, no G2+ CRS, no ICANS. Median f/u 244 days, 1 pt w/ molR at 6m post-CAR T-cells. No deaths or other relapses. Very short f/u (only 2 post-12 months). Interesting approach for short course tx in hard-to-treat group of pts. 2/2 #ash24 #allsm
December 10, 2024 at 1:55 AM
vjhemonc.bsky.social
Want the latest expert insights about CAR-T in ALL?💉🩸

Then check out our recent discussion from #iwCART25, in which leading experts Claire Roddie, Rebecca Gardner, Bijal Shah, & Noelle Frey provide their insights:

👉 buff.ly/Evw2bXJ

#ALLsm #Leusm #CARTCell #HemOnc #BloodSky #HemeSky #MedSky
May 12, 2025 at 3:04 PM
markgeyermd.bsky.social
EOC: 87% MRD negative. 3-year EFS 67.7%. Most common AEs shown below. Unclear if early MRD negativity might achieve similar benefit to alloHCT, especially in the younger pts. 3/3 #allsm #ash24
December 9, 2024 at 11:56 PM
markgeyermd.bsky.social
Outcomes were poor in those w/ tMN, even among those undergoing alloHCT. 8/9 pts w/ paired sequencing data had shared molecular alterations between ALL and tMN (cells not sorted). 3/3 #ASH24 #allsm
December 9, 2024 at 6:58 PM